urea/infarction

The invention relates to urea and/or urethane derivatives of the formula I ##STR00001## in which TABLE-US-00001 X is O or NR.sup.5, Y is --N(R.sup.5)R.sup.4, --C(.dbd.NR.sup.7)--NHR.sup.7 or --C(.dbd.NR.sup.9)--NHR.sup.7, B ##STR00002## R is H, A, cycloalkyl, Ar, arylalkyl or Pol, R.sup.1 is OR or

The invention relates to amide and urea derivatives of the formula I in which R.sup.1 is 3-indolyl which is unsubstituted or mono- or disubstituted by A, AO, OH, Hal, CN, NO.sub.2, NH.sub.2, NHA, NA.sub.2, COA, CONH.sub.2, CONHA, CONA.sub.2, CH.sub.2 OH, CH.sub.2 OA, CH.sub.2 NH.sub.2, CH.sub.2 NHA,

DESCRIPTION Urea-substituted benzoylguanidines, process for their preparation, their use as pharmaceutical or diagnostic, and pharmaceutical containing them. The invention relates to benzoylguanidines of the formula I ##STR3## in which: R(1), R(3) or R(4) is --NR(6) C.dbd.X NR(7)R(8), X is oxygen,

FIELD OF THE INVENTION The present invention relates to certain diaryl and arylheteroaryl urea derivatives of Formula (I) and pharmaceutical compositions thereof that modulate the activity of the 5-HT.sub.2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to

FIELD OF THE INVENTION The present invention relates to certain diaryl and arylheteroaryl urea derivatives of Formula (I) and pharmaceutical compositions thereof that modulate the activity of the 5-HT.sub.2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to

FIELD OF THE INVENTION The present invention relates to certain diaryl and arylheteroaryl urea derivatives of Formula (I) and pharmaceutical compositions thereof that modulate the activity of the 5-HT.sub.2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to

FIELD OF THE INVENTION The present invention relates to certain diaryl and arylheteroaryl urea derivatives of Formula (I) and pharmaceutical compositions thereof that modulate the activity of the 5-HT.sub.2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to

FIELD OF THE INVENTION This invention relates to a new class of compounds, which are potent and highly selective inhibitors of factor Xa, both isolated and when assembled in a complex with other proteins. In another aspect the invention relates to a new class of compounds, their pharmaceutically

FIELD OF THE INVENTION The present invention concerns novel urea and thiourea derivatives of substituted quinoxaline 2,3-diones having utility as glutamate receptor antagonists. The fused ring quinoxaline 2,3-dione system is substituted at the a- or b-position by urea or thiourea derivatives. The

PRIORITY This application is a national phase filing of the Patent Cooperation Treaty (PCT) application # PCT/IB2013/050904 titled COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC SYNDROME filed on Feb. 3, 2013 Published with WIPO Publication # WO/2013/167996, which further claims priority to

PRIORITY The present application claims the benefit of Indian Provisional Patent Application No. 1836/CHE/2012 filed on 10 May 2012 and the International Application No. PCT/IB2013/050907 filed on 3 Feb. 2013; the entire disclosure of which is relied on for all purposes and is incorporated into this

TECHNICAL FIELD The present invention relates to a method for producing an isoquinoline derivative or a salt thereof which is useful for preventing and treating cerebrovascular disorders such as cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage, and cerebral edema, particularly as a

This application is a National Stage of PCT/JP11/069,187 filed Aug. 25, 2011 and claims the benefit of JP 2010-189392 filed Aug. 26, 2010. TECHNICAL FIELD The present invention relates to a method for producing an isoquinoline derivative or a salt thereof which is useful for preventing and treating

BACKGROUND OF THE INVENTION 1. Field of the Invention The invention relates generally to prevention and treatment of atherosclerosis, myocardial infarction and related conditions such as peripheral vascular disease and ischemic stroke, and specifically to drugs that increase levels of HDL. 2.